22:34 , Mar 29, 2019 |  BC Extra  |  Clinical News

Pfizer's ketohexokinase inhibitor decreases liver fat content in NAFLD Phase II

As Pfizer considers which combination therapies to develop for NASH, the pharma reported that its KHK inhibitor, PF-06835919, as monotherapy reduced whole liver fat in a Phase II trial to treat non-alcoholic fatty liver disease....
02:27 , Nov 3, 2018 |  BioCentury  |  Product Development

New partners for NASH

Pharmas are loading up their NASH portfolios expecting that addressing the full disease spectrum will require combinations, though the field lacks the tools to sort the different mechanisms on offer strategically. Meanwhile, at least three...
19:53 , Nov 2, 2018 |  BC Week In Review  |  Company News

Pfizer, Novartis in NASH deal with multiple MOAs

Pfizer Inc. (NYSE:PFE) and Novartis AG (NYSE:NVS; SIX:NOVN) partnered to test Novartis' tropifexor (LJN452) in combination with three compounds from Pfizer with different mechanisms of action to treat non-alcoholic steatohepatitis. The partners will conduct preclinical...
20:30 , Oct 29, 2018 |  BC Extra  |  Company News

Pfizer, Novartis in NASH deal with multiple MOAs

Pfizer Inc. (NYSE:PFE) and Novartis AG (NYSE:NVS; SIX:NOVN) partnered to test Novartis' tropifexor (LJN452) in combination with three compounds from Pfizer with different mechanisms of action to treat non-alcoholic steatohepatitis. The partners will conduct preclinical...
16:18 , May 3, 2018 |  BC Innovations  |  Distillery Therapeutics

Endocrine/metabolic

INDICATION: Endocrine/metabolic Mouse studies suggest KHK inhibitors could help treat hereditary fructose intolerance. In a mouse model of hereditary fructose intolerance, systemic KHK knockout decreased hypoglycemia, fibrosis and inflammation in the liver compared with normal...
18:44 , Nov 27, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Mouse studies suggest inhibiting the metabolic enzymes ketohexokinase, NADK or SUCLA2 could help treat KRAS-mutant colorectal cancer. In a xenograft mouse model of KRAS-mutant colorectal cancer, screening of a CRISPR guide RNA...
01:01 , Apr 28, 2017 |  BC Innovations  |  Finance

1Q17 public-private partnership roundup

This quarter’s deal-making in public-private partnerships (PPPs) picked up from the slow rate in the second half of last year, with 1Q17 activity comparable to that seen at the start of last year. Led by...
07:00 , Jun 17, 2013 |  BioCentury  |  Strategy

Grounded in Japan

Amgen Inc. has been developing products in Japan via JVs and partnerships since the early 1980s. Now a new joint venture with Astellas Pharma Inc. will allow the biotech to build its first commercial presence...
07:00 , Mar 18, 2013 |  BioCentury  |  Strategy

Japan's biggest biotech

Japanese pharmaceutical companies have historically been thought of as stodgy, insular and opaque, but that is changing fast. One year into the job, Kyowa Hakko Kirin Co. Ltd. 's CEO is building his company along...
07:00 , Mar 29, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Metabolic syndrome; obesity Fructokinase (ketohexokinase; KHK) Mouse studies suggest antagonizing the C isoform of fructokinase could help treat metabolic syndrome...